Cover Image
Read Now

Point-of-care troponin testing in patients with symptoms suggestive of acute coronary syndrome: A health technology assessment

Testing of cardiac biomarkers, such as cardiac troponin I or cardiac troponin T, has an important role in the diagnostic workup for acute coronary syndrome (ACS) (including acute myocardial infarction [AMI] and unstable angina), and in patients presenting with acute chest pain and a non-diagnostic e...

Full description

Bibliographic Details
Main Author: Ho, Chuong
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2016, [March 2016]
Series:CADTH optimal use report
Subjects:
Troponin T / Therapeutic Use
Point-of-care Systems / Standards
Cost-benefit Analysis
Acute Coronary Syndrome / Diagnosis
Troponin I / Therapeutic Use
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 02270nam a2200313 u 4500
001 EB001840057
003 EBX01000000000000001004046
005 00000000000000.0
007 tu|||||||||||||||||||||
008 180702 r ||| eng
100 1 |a Ho, Chuong 
245 0 0 |a Point-of-care troponin testing in patients with symptoms suggestive of acute coronary syndrome: A health technology assessment  |h Elektronische Ressource  |c clinical authors, Chuong Ho, Karen Cimon, Laura Weeks, Monika Mierzwinski-Urban, Lesley Dunfield, economic authors, Lesley Soril, Fiona Clement, Mohammed Jabr 
246 3 1 |a Health technology assessment 
260 |a Ottawa (ON)  |b Canadian Agency for Drugs and Technologies in Health  |c 2016, [March 2016] 
300 |a 1 PDF file (ix, 133 pages)  |b illustrations 
505 0 |a Includes bibliographical references 
653 |a Troponin T / therapeutic use 
653 |a Point-of-Care Systems / standards 
653 |a Cost-Benefit Analysis 
653 |a Acute Coronary Syndrome / diagnosis 
653 |a Troponin I / therapeutic use 
710 2 |a Canadian Agency for Drugs and Technologies in Health 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a CADTH optimal use report 
500 |a "PROSPERO Registration Number: CRD42015023442." 
856 4 0 |u https://www.ncbi.nlm.nih.gov/books/NBK362840  |3 Volltext  |n NLM Bookshelf Books  |3 Volltext 
082 0 |a 610 
520 |a Testing of cardiac biomarkers, such as cardiac troponin I or cardiac troponin T, has an important role in the diagnostic workup for acute coronary syndrome (ACS) (including acute myocardial infarction [AMI] and unstable angina), and in patients presenting with acute chest pain and a non-diagnostic electrocardiogram (ECG). Bedside testing of cardiac troponins (cTn) using point-of-care (POC) assays was developed to reduce the turnaround time of the standard tests performed in a central laboratory, and to expedite treatment. Given the introduction and increasing diffusion of POC cTn use, a review of its clinical and economic evidence is needed to inform decisions about its acquisition and use in emergency rooms and other in-hospital settings, as well as in rural health care centres and remote settings 

Similar Items